Pelacarsen
TQJ230 / IONIS-APO(a)-LRxFirst Lp(a)-lowering therapy to reach Phase 3. HORIZON CV outcomes trial enrolling 8,323 patients with elevated Lp(a) and established ASCVD.
Target: LPA GalNAc-conjugated antisense oligonucleotide (ASO) Novartis Pharmaceuticals Cardiometabolic
When will we know if it works?
AwaitingA positive readout makes LPA a validated target for the first time. Hover the badge above for what the confidence level means.
7
Phase 3 trials
5 active · 2 completed
10
Total trials
P2: 0 · P1: 3
8,323
Max trial size
across 9 indications
2
Sponsors at target
incl. 4 other assets
What does it do?
LPA — Apolipoprotein(a) — Lipoprotein(a) component
Modality: GalNAc-conjugated antisense oligonucleotide (ASO)
Program: HORIZON (Lp(a)-HORIZON)
The 7 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT04023552 | Cardiovascular Disease and Lipoprotein(a) | 8,323 | ACTIVE_NOT_RECRUITING | 2019-12-12 | 2026-06-30 | Fresh est. |
| NCT05305664 | Hyperlipoproteinemia(a) | 51 | COMPLETED | 2022-08-19 | 2025-01-28 (actual) | Awaiting |
| NCT05900141 | Hyperlipoproteinemia (a) | 41 | ACTIVE_NOT_RECRUITING | 2023-09-29 | 2028-08-24 | Aging est. |
| NCT06267560 | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | 422 | COMPLETED | 2024-04-24 | 2026-03-25 (actual) | Awaiting |
| NCT06813911 | Atherosclerotic Cardiovascular Disease (ASCVD) | 340 | RECRUITING | 2025-04-30 | 2028-02-03 | Fresh est. |
| NCT06875973 | Atherosclerotic Cardiovascular Disease | 599 | RECRUITING | 2025-05-19 | 2030-12-08 | Fresh est. |
| NCT07517263 | Cardiovascular Disease and Lipoprotein(a) | 5,700 | RECRUITING | 2026-04-13 | 2030-01-09 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2019 | license | Ionis Pharmaceuticals | $150M upfront + milestones |
What's the case for and against?
✓ What's working in its favor
- Phase 2: ~80% reduction in Lp(a) at 80mg dose
- First ASO to enter P3 for cardiovascular outcomes specifically targeting Lp(a)
Who else is racing? — 4 other assets at LPA
| Asset | Sponsor | Status |
|---|---|---|
| Muvalaplin | Eli Lilly | P3 active (oral small molecule) |
| Olpasiran | Amgen | P3 OCEAN(a)-Outcomes |
| SLN360 (Zerlasiran) | Silence Therapeutics | P2 readout positive 2024 |
| SRSD216 | Sirius Therapeutics (China) | P2 |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.